Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.

Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.
Reference: Leneghan, DB, Miura, K, Taylor, IJ et al., (2017). Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Scientific Reports, 7 (1), 3811.Citable link to this page:
Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.
Abstract: Vaccine development efforts have recently focused on enabling strong immune responses to poorly immunogenic antigens, via display on multimerisation scaffolds or virus like particles (VLPs). Typically such studies demonstrate improved antibody titer comparing monomeric and nano-arrayed antigen. There are many such studies and scaffold technologies, but minimal side-by-side evaluation of platforms for both the amount and efficacy of antibodies induced. Here we present direct comparison of three leading platforms displaying the promising malaria transmission-blocking vaccine (TBV) target Pfs25. These platforms encompass the three important routes to antigen-scaffold linkage: genetic fusion, chemical cross-linking and plug-and-display SpyTag/SpyCatcher conjugation. We demonstrate that chemically-conjugated Qβ VLPs elicited the highest quantity of antibodies, while SpyCatcher-AP205-VLPs elicited the highest quality anti-Pfs25 antibodies for transmission blocking upon mosquito feeding. These quantative and qualitative features will guide future nanoassembly optimisation, as well as the development of the new generation of malaria vaccines targeting transmission.
Publication status:PublishedPeer Review status:Peer reviewedVersion:Publisher's versionDate of acceptance:2017-05-04 Funder: Nuffield Department of Medicine Funder: Jenner Institute Funder: St. Catherine’s College, Oxford Funder: PATH Malaria Vaccine Initiative Funder: National Institutes of Health Funder: University of Oxford Department of Biochemistry Notes:© The Author(s) 2017. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Bibliographic Details
Publisher: Nature Publishing Group
Publisher Website: https://www.nature.com/
Journal: Scientific Reportssee more from them
Publication Website: https://www.nature.com/srep
Volume: 7
Issue: 1
Issue Date: 2017-06
pages:3811Identifiers
Doi: https://doi.org/10.1038/s41598-017-03798-3
Issn: 2045-2322
Uuid: uuid:bf81167a-0d78-42d6-9b16-9fe109031b88
Urn: uri:bf81167a-0d78-42d6-9b16-9fe109031b88
Pubs-id: pubs:702078 Item Description
Type: journal-article;
Language: eng
Version: Publisher's versionKeywords: Journal Article
Relationships
Autor: Leneghan, DB - - - Miura, K - - - Taylor, IJ - Oxford, MSD, NDM, Jenner Institute - - - Li, Y - Oxford, MSD, NDM, Jenner Institut
Fuente: https://ora.ox.ac.uk/objects/uuid:bf81167a-0d78-42d6-9b16-9fe109031b88